Major salivary gland carcinoma
diseaseOn this page
Also known as carcinoma of Major salivary glandcarcinoma of the major salivary glandmajor salivary gland cancer
Summary
Major salivary gland carcinoma (MONDO:0006284) is a cancer (an umbrella term covering 6 Mondo subtypes) and 16 clinical trials. Top therapeutic interventions include dasatinib anhydrous, trastuzumab deruxtecan, and cisplatin. A subtype of salivary gland carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 6 Mondo subtypes
- Clinical trials: 16
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | major salivary gland carcinoma |
| Mondo ID | MONDO:0006284 |
| EFO | EFO:1000344 |
| NCIT | C5907 |
| UMLS | C1334549 |
| MedGen | 235287 |
| GARD | 0027745 |
| Anatomy (UBERON) | UBERON:0001829 |
| Is cancer (heuristic) | yes |
Also known as: carcinoma of Major salivary gland · carcinoma of major salivary gland · carcinoma of the major salivary gland · major salivary gland cancer · major salivary gland carcinoma
Disease family
This is a subtype of salivary gland carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › oral cavity cancer › salivary gland cancer › salivary gland carcinoma › major salivary gland carcinoma
Related subtypes (12): salivary gland adenoid cystic carcinoma, salivary gland basal cell adenocarcinoma, salivary gland carcinoma ex pleomorphic adenoma, salivary gland large cell carcinoma, salivary gland small cell carcinoma, salivary gland epithelial myoepithelial carcinoma, salivary gland mucoepidermoid carcinoma, salivary gland squamous cell carcinoma, salivary duct carcinoma, minor salivary gland carcinoma, salivary gland mucinous adenocarcinoma, mammary analog secretory carcinoma
Subtypes (6): submandibular gland cancer, major salivary gland carcinoma ex pleomorphic adenoma, major salivary gland mucoepidermoid carcinoma, sublingual gland carcinoma, carcinoma of parotid gland, major salivary gland adenoid cystic carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 16.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 9 |
| PHASE1 | 3 |
| PHASE1/PHASE2 | 2 |
| PHASE3 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00588770 | PHASE3 | ACTIVE_NOT_RECRUITING | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
| NCT02834013 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
| NCT04895735 | PHASE2 | ACTIVE_NOT_RECRUITING | MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer |
| NCT05408845 | PHASE2 | RECRUITING | Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers |
| NCT00458978 | PHASE2 | COMPLETED | Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer |
| NCT00859937 | PHASE2 | COMPLETED | Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors |
| NCT01175980 | PHASE2 | COMPLETED | Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma |
| NCT01256385 | PHASE2 | COMPLETED | Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy |
| NCT01604772 | PHASE2 | COMPLETED | Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma |
| NCT02538510 | PHASE1/PHASE2 | COMPLETED | Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery |
| NCT03146650 | PHASE2 | UNKNOWN | Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer |
| NCT03749460 | PHASE1/PHASE2 | COMPLETED | Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers |
| NCT04576091 | PHASE1 | ACTIVE_NOT_RECRUITING | Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer |
| NCT04704661 | PHASE1 | ACTIVE_NOT_RECRUITING | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial |
| NCT01254617 | PHASE1 | COMPLETED | Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer |
| NCT01365169 | Not specified | RECRUITING | Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DASATINIB ANHYDROUS | 4 | 2 |
| TRASTUZUMAB DERUXTECAN | 4 | 2 |
| CISPLATIN | 4 | 1 |
| TEMSIROLIMUS | 4 | 1 |
| TRASTUZUMAB EMTANSINE | 4 | 1 |
| VORINOSTAT | 4 | 1 |
| CEDIRANIB MALEATE | 3 | 1 |
| CERALASERTIB | 3 | 1 |
| ELIMUSERTIB | 1 | 1 |
| CHEMBL4583196 | 0 | 1 |